Mountain View, CA 3/1/17—Takara Bio USA (TBUSA) has completed its acquisition of publicly held WaferGen Bio-systems (see IBO 3/15/16). WaferGen provides technology for isolating and processing single cells. The final purchase price was $35.9 million. “We are excited about the synergy between WaferGen’s technologies and products for isolation and processing of single cells and our RNA-seq and T-Cell Receptor profiling technologies,” commented TBUSA President Carol Lou. “WaferGen’s technologies are highly complementary to our reagent portfolio and the combination presents new opportunities for us in genetic analysis including clinical and applied markets.” 

This month, WaferGen announced preliminary 2016 revenues grew 48.6% to $10.7 million. The company estimated accumulated operating losses of $119.8 million, as of September 30, 2016. With the purchase, Takara Bio obtains microfluidic technology, including systems for NGS sample preparation. WaferGen delisted from the NASDAQ Stock Exchange on February 28.